The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

A.V. Gavrilenko

B.V. Petrovsky Russian Scientific Center of Surgery, Moscow, Russia;
Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Health of the Russia, Moscow, Russia

D.A. Voronov

acad. B.V. Petrovskiy Russian Scientific Center for Surgery of RAS;
acad. B.V. Petrovskiy Chair of Cardiovascular Surgery №1 of I.M. Sechenov First Moscow State Medical University, Moscow, Russia

E.Iu. Alikin

Rossiĭskiĭ nauchnyĭ tsentr khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Prevention of venous thrombosis in surgical practice: current points and future issues

Authors:

A.V. Gavrilenko, D.A. Voronov, E.Iu. Alikin

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2010;(11): 62‑70

Read: 953 times

Contact the author
Table of contents

PREVENTION OF VENOUS THROMBOSIS IN SURGICAL PRACTICE: CURRENT POINTS AND FUTURE ISSUES
PREVENTION OF VENOUS THROMBOSIS IN SURGICAL PRACTICE: CURRENT POINTS AND FUTURE ISSUES

To cite this article:

Gavrilenko AV, Voronov DA, Alikin EIu. Prevention of venous thrombosis in surgical practice: current points and future issues. Pirogov Russian Journal of Surgery. 2010;(11):62‑70. (In Russ.)

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Arti­ficial inte­lligence in surgery. Redu­cing the risks rela­ted to poly­pharmacy in perioperative period. Piro­gov Russian Journal of Surgery. 2025;(7):59-66
Anti­reflex endo­tracheal tube in clinical practice. Russian Journal of Anesthesiology and Reanimatology. 2025;(4):54-60
Prevention and treatment of dermal toxi­city in children receiving anti-tumor radiation. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):470-480
Burnout syndrome: prevention, treatment and reha­bilitation. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):61-68
Thyroid mini-access on the ante­rior surface of the neck (anatomo-clinical study). Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(3):29-40
The use of grape poly­phenols in combination with magnetic therapy in patients with bronchial asthma who have suffered a new coro­navirus infe­ction. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):14-19
Sagi­ttal sinus thro­mbosis during pregnancy with the deve­lopment of ischemic stroke. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):87-91
Beautiful rela­tionship between art and medi­cine: from clay mode­ling to auri­cular cartilage mode­ling. Plastic Surgery and Aesthetic Medi­cine. 2025;(3-2):71-77
Prevention of sero­mas after abdo­minoplasty. Plastic Surgery and Aesthetic Medi­cine. 2025;(3-2):97-103
The impo­rtance of screening preventive examination at the outpatient stage. Russian Journal of Preventive Medi­cine. 2025;(10):99-102
Abstract:

Keywords:

surgery
thromboprophylaxis
anticoagulants

Authors:

A.V. Gavrilenko

B.V. Petrovsky Russian Scientific Center of Surgery, Moscow, Russia;
Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Health of the Russia, Moscow, Russia

D.A. Voronov

acad. B.V. Petrovskiy Russian Scientific Center for Surgery of RAS;
acad. B.V. Petrovskiy Chair of Cardiovascular Surgery №1 of I.M. Sechenov First Moscow State Medical University, Moscow, Russia

E.Iu. Alikin

Rossiĭskiĭ nauchnyĭ tsentr khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Close metadata

References:

  1. Moiseev V.S. Nizkomolekulyarnyi geparin. Klin farmakol 2000;9:1:72-79.
  2. Rumyantsev A.G., Pashanov E.D. Profilaktika tromboza glubokikh ven i tromboembolii legochnoi arterii. M 2006.
  3. Savel'ev V.S. Flebologiya M: Meditsina 2001.
  4. Bergqvist D., Burmark U.S., Flordal P.A. Low molecular weight heparin started before(1) surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg 1995;82:4:496-501.
  5. Bounameaux H., Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002;359:9319: 1710-1711.
  6. Bousser M.G., Bouthier J., Buller H.R. et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371:9609:315-321.
  7. Buller H.R., Cohen A.T., Davidson B. et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:11:1094-104.
  8. Cannegieter S.C., Rosendaal F.R., Wintzen A.R. et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
  9. Caprini J.A., Hwang E., Hantel S. et al.  The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopaedic surgery. J Thromb Haemost 2007;5:Abstract O-W-050.
  10. Crowther M.A., Ginsberg J., Kearon C. et al. A randomized trial comparing 5 mg and 10 mg warfarin loading doses. Arch Int Med 1999;159:46-48.
  11. Crowther M.A., Julian J., Douketis J.D. et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized clinical trial. Lancet 2000;356:1551-1553.
  12. Eriksson B.I., Borris L., Dahl O.E. et al. Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-128.
  13. Eriksson B.I., Borris L.C., Dahl O.E. et al.  A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-2381.
  14. Eriksson B.I., Borris L.C., Friedman R.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:26:2765-2775.
  15. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 2007;370:9591:949-956.
  16. Eriksson B.I., Dahl O.E., Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007;5:11:2178-2185.
  17. Fihn S.D., Callahan C.M., Martin D.C. et al.  The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation. Ann Int Med 1996;124:970-979.
  18. Frydman A. low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humanal. Haemostasis 1996;26:Suppl 12:24-38.
  19. Ginsberg J.S., Davidson B.L., Comp P.C. et al. The oral thrombin inhibitor dabigatran etexilate vs the North-American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2008.
  20. Graff J., von Hentig N., Misselwitz F. et al. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398-1407.
  21. Gurwitz J.H., Avorn J., Ross-Degnan D. et al. Aging and the anticoagulant response to warfarin therapy. Ann Int Med  1992;116:901-904.
  22. Gurwitz J.H., Field T.S., Radford M.J. et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007;120:539-544.
  23. Gustafsson D., Nystrom J., Carlsson S. et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-181.
  24. Harrison L., Johnston M., Massicotte M.P. et al.  Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Int Med 1997;126:133-136.
  25. Hauel N.H., Nar H., Priepke H. et al.  Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002;45:1757-1766.
  26. Hawkins D. Limitations of traditional anticoagulants. Pharmacotherapy 2004;24:62S-65S.
  27. He K., He B., Grace J.E. et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor. Blood 2006;108:Abstract 910.
  28. Hirsh J., Guyatt G., Albers G.W. et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest 2004;126:172S-173S.
  29. Hirsh J., O'Donnell M., Eikelboom J.W.  Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007;116:552-560.
  30. Hirsh J., O'Donnell M., Weitz J.I.  New anticoagulants. Blood 2005;105:453-463.
  31. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
  32. Hull R., Hirsh J., Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
  33. Hylek E.M., Chang Y.C., Skates S.J. et al.  Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Int Med 2000;160:1612-1617.
  34. Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994;120:897-902.
  35. Jeffrey I., Weitz J.H., Meyer M.S. et al. Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease. Haemostasis 1999;28:62-68.
  36. Kakkar A.K., Brenner B., Dahl O.E. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:9632:31-39.
  37. Kearon C., Kahn S., Agnelli G. et al.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:454S-545S.
  38. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-328.
  39. Lassen M.R., Ageno W., Borris L.C. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:26:2776-2786.
  40. Makris M., Greaves M., Phillips W.S. et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480.
  41. Nordstrom M., Lindblad B., Bergqvist D. et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Int Med 1992;232:155-160.
  42. O'Connell M.B., Kowal P.R., Allivato C.J., Repka T.L. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 2000;20:923-930.
  43. Savi P., Chong B.H., Greinhacher A. et al. Prevention of venous thromboembolism. Chest 2001;119:Suppl 1:1329-1759.
  44. Savi P., Chong B.H., Greinhacher A. et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractioned heparin. Blood 2005;105:139-144.
  45. Simonneau G., Laporte S., Mismetti P. et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
  46. Stangier J., Eriksson B.I., Dahl O.E. et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-563.
  47. Turpie A.G., Bauer K.A., Eriksson B.I. et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double blind studies. Arch Int Med 2002;162:1833-1840.
  48. Turpie A.G., Bauer K.A., Davidson B. et al. Comparison of rivaroxaban, an oral direct Factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study). 2008: Proceedings of the 9th EFORT Congress, Nice 2008;Abstract F85.
  49. Turpie A.G.  Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-1247.
  50. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:25:2653-2655.
  51. Weitz J., Hirsh J., Samama M.M. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008;133:234S-256S.
  52. Geerts W.H., Bergqvist D., Pineo G.F. et al.  Colwell prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2008;133:381S-453S.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.